Tenet Healthcare Corporation (THC) SEC Filings & Earnings Calls
EquiReason read 18 Tenet Healthcare Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-09-22 — Tenet Healthcare entered into a Forty-Third Supplemental Indenture for existing debt; no new issuance or material change disclosed..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 21.6B
- P/E TTM
- 10.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
8 Sep 20268-K · 7.01, 8.01Tenet Healthcare upsized and priced $2.0B private offering of 6.250% Senior Notes due 2034; proceeds to redeem $1.5B 2027 notes and $0.5B 2028 notes.open
Figures in the filing · each found in the filing text
| aggregate principal amount of notes · 2026-09-08 | $2.00B | |
| interest rate · 2026-09-08 | 6.3% |
Risks flagged
Refinancing reduces secured debt but increases total debt; interest rate of 6.25% is higher than redeemed notes' coupons (5.125% and 6.125%), potentially increasing interest expense.
“New notes at 6.250% vs redeemed 2027 notes at 5.125% and 2028 notes at 6.125%.”
29 Jul 202610-QTenet Healthcare reported strong Q2 2026 results with revenue growth of 6.8% YoY, significant margin expansion, and a major contract termination agreement with CHI providing $826M in revenue.earningsopen
Figures in the filing · each found in the filing text
| Net operating revenues · Consolidated · Q2-2026 | $5.63B | +7% y/y |
| Net income available to Tenet Healthcare Corporation common shareholders · Consolidated · Q2-2026 | $826M | +187% y/y |
| Net cash provided by operating activities · Consolidated · H1-2026 | $2.23B | +27% y/y |
| Hospital Operations Adjusted EBITDA · Hospital Operations · Q2-2026 | $762M | +22% y/y |
| Ambulatory Care Adjusted EBITDA · Ambulatory Care · Q2-2026 | $542M | +9% y/y |
| Total admissions · Hospital Operations · Q2-2026 | 120,290 | +3% y/y |
| Ambulatory Care total consolidated cases · Ambulatory Care · Q2-2026 | 512,979 | +5% y/y |
| Share repurchases · Consolidated · H1-2026 | 7,021,000 |
Guidance
FY2026 capex guided $700M-$800M
Management reaffirms positive outlook with strong volume trends, margin improvement, and significant capital return to shareholders via buybacks.
Risks flagged
Medicaid Funding Reduction
“The OBBBA’s legislative and forthcoming regulatory changes may result in material reductions to Medicaid payments, changes and reductions to Medicaid supplemental payment programs, and payment delays.” · word for word
Payer Mix Deterioration
“The increase of $239 million, or 6.0%, in our Hospital Operations segment’s net operating revenues for the three‑month period in 2026, as compared to the same period in 2025, was primarily attributable to higher patient volumes, partially offset by a less favorable payer mix, during the 2026 period.” · word for word
Regulatory Compliance Cost
“We continue to monitor developments affecting Medicaid funding, health insurance marketplace enrollment and payer mix, as well as the influence of geopolitical dynamics, trade tensions, tariffs and export control rules on pricing and availability within global supply chains.” · word for word
23 Jul 20268-K · 2.02Net income available to common shareholders $826M (+187% y/y); Adjusted EBITDA $1.30B (+16% y/y); Adjusted diluted EPS $6.12 (+52% y/y); Guidance: FY2026 Adjusted EBITDA midpoint raised by $295M to $4.93B; Adjusted FCF midpoint raised by $2earningsopen
Figures in the filing · each found in the filing text
| Net income available to common shareholders · Q2-2026 | $826M | +187% y/y |
| Adjusted EBITDA · Q2-2026 | $1.30B | +16% y/y |
| Adjusted diluted EPS · Q2-2026 | $6.12 | +52% y/y |
| Ambulatory Care Adjusted EBITDA · Ambulatory Care · Q2-2026 | $542M | +9% y/y |
| Hospital Adjusted EBITDA margin · Hospital · Q2-2026 | 18.0% | |
| Adjusted free cash flow (six months) · H1-2026 | $1.42B | -3% y/y |
| Share repurchases (quarter) · Q2-2026 | $1.04B |
Guidance
FY2026 Adjusted EBITDA midpoint raised by $295M to $4.93B; Adjusted FCF midpoint raised by $225M to $2.875B
Strong Q2 beat and raised guidance driven by same-store revenue growth and margin expansion
Risks flagged
Payer mix headwinds from lower exchange admissions
“partially offset by unfavorable payer mix due to lower exchange admissions” · word for word
30 Apr 20268-K · 2.02Net operating revenues $5.37B (+3% y/y); Net income available to common shareholders $702M (+73% y/y); Adjusted diluted EPS $4.82 (+11% y/y); Guidance: FY2026 Adjusted EBITDA outlook continues to be in the range of $4.485 billion to $4.785earningsopen
Figures in the filing · each found in the filing text
| Net operating revenues · Q1-2026 | $5.37B | +3% y/y |
| Net income available to common shareholders · Q1-2026 | $702M | +73% y/y |
| Adjusted diluted EPS · Q1-2026 | $4.82 | +11% y/y |
| Adjusted EBITDA · Q1-2026 | $1.16B | -0% y/y |
| Ambulatory Care Adjusted EBITDA · Ambulatory Care · Q1-2026 | $484M | +6% y/y |
Guidance
FY2026 Adjusted EBITDA outlook continues to be in the range of $4.485 billion to $4.785 billion
Strong Q1 results with significant EPS growth; FY guidance reaffirmed; Ambulatory segment performing well; strong free cash flow
Risks flagged
Unfavorable payer mix due to lower exchange admissions
“strong growth in same facility revenue and disciplined expense management offset by unfavorable payer mix due to lower exchange admissions” · word for word
CommonSpirit contract conclusion impact
“the Company recognized an approximate $40 million favorable non-recurring pre-tax impact associated with the recognition of previously deferred revenue, and $413 million of revenue ($314 million after-tax) from early contract conclusion” · word for word
30 Apr 202610-QOperating income $1.30B (+37% y/y); Operating cash flow $1.64B (+101% y/y); Capital expenditures $180M (+4% y/y); Guidance: FY2026 capex guided $700M-$800Mopen
Figures in the filing · each found in the filing text
| Operating income · Q1-2026 | $1.30B | +37% y/y |
| Operating cash flow · Q1-2026 | $1.64B | +101% y/y |
| Capital expenditures · Q1-2026 | $180M | +4% y/y |
| Ambulatory Care same-facility net revenue per case · Ambulatory Care · Q1-2026 | 5.6% | |
| Ambulatory Care same-facility cases · Ambulatory Care · Q1-2026 | -0.3% | |
| Total admissions · Hospital Operations · Q1-2026 | 120,899 | +1% y/y |
| Share repurchase · Q1-2026 | 1,346,000 |
Guidance
FY2026 capex guided $700M-$800M
No explicit revenue or earnings guidance provided; capex guidance implies continued investment. Management tone positive on ambulatory growth but cautious on policy headwinds.
Risks flagged
Medicaid/Insurance Coverage Loss
“we expect an adverse impact on our patient volumes, payer mix and revenues” · word for word
Payer Mix Deterioration
“partially offset by a less favorable payer mix during the 2026 period” · word for word
Supply Cost Inflation
“Supplies expense for our Hospital Operations segment increased by $15 million, or 2.5%” · word for word
16 Apr 2026DEF 14AProxy statement for 2026 annual meeting, disclosing executive compensation structure and 2025 performance.open
Figures in the filing · each found in the filing text
| Adjusted EBITDA Margin · FY2025 | 21.4% | |
| Free Cash Flow after NCI Distributions · FY2025 | $1.72B | |
| Same-Hospital Net Patient Revenue Growth · Hospital Operations · FY2025 | 6.6% | |
| USPI Same-Facility Revenue Growth · Ambulatory Care · FY2025 | 7.2% | |
| USPI Facility Count · Ambulatory Care · FY2025 | 559 | |
| Share Repurchases · FY2025 | $1.40B | |
| Leverage Ratio · FY2025 | $2.25 | |
| Net Income Available to Common Shareholders · FY2025 | $1.41B | |
| Adjusted Diluted EPS · FY2025 | $16.78 | |
| Net Operating Revenues · FY2025 | $21.31B |
Risks flagged
Regulatory and Compliance Risk
“Regulatory developments or weather-related events may increase operating costs or disrupt operations.” · word for word
Litigation and Investigation Costs
“Litigation and investigation costs (64) (35) (47)” · word for word
10 Apr 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Low risk; transition is planned and extended.
“Retirement effective Dec 31, 2026, with part-time transition through Apr 1, 2028.”
30 Mar 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Low risk; orderly succession with experienced hire.
“New controller has relevant experience from Lifepoint Health and KPMG.”
17 Feb 202610-KOperating Cash Flow $3.54B (+73% y/y); Number of ASCs 533; Ambulatory Care Cases 512,778 (+8% y/y)open
Figures in the filing · each found in the filing text
| Operating Cash Flow · FY2025 | $3.54B | +73% y/y |
| Number of ASCs · Ambulatory Care · 2025-12-31 | 533 | |
| Ambulatory Care Cases · Ambulatory Care · Q4-2025 | 512,778 | +8% y/y |
| Hospital Operations Revenue · Hospital Operations · Q4-2025 | $4.09B | +7% y/y |
| Ambulatory Care Revenue · Ambulatory Care · Q4-2025 | $1.43B | +14% y/y |
| Share Repurchases · FY2025 | $1.39B |
Risks flagged
Medicaid Funding Reduction Risk
“the OBBBA introduces new limitations and eligibility requirements that are expected to materially impact Medicaid funding (including supplemental payments) and enrollment” · word for word
Medical Supply Inflation Risk
“inflation specific to medical supply prices remained high due to current economic conditions and other factors” · word for word
Regulatory and Legislative Uncertainty
“The healthcare industry remains subject to significant legislative and regulatory uncertainty.” · word for word
Conifer Contract Termination Risk
“terminate the amended and restated master services agreement pursuant to which Conifer provides end-to-end revenue cycle management services to certain CHI facilities effective as of December 31, 2026” · word for word
11 Feb 20268-K · 2.02Net operating revenues $5.53B (+9% y/y); Net income available to Tenet common shareholders $371M (+17% y/y); Adjusted diluted earnings per share $4.70 (+37% y/y); Guidance: FY2026 Adjusted EBITDA outlook $4.485B-$4.785B vs FY2025 $4.566Bearningsopen
Figures in the filing · each found in the filing text
| Net operating revenues · Q4-2025 | $5.53B | +9% y/y |
| Net income available to Tenet common shareholders · Q4-2025 | $371M | +17% y/y |
| Adjusted diluted earnings per share · Q4-2025 | $4.70 | +37% y/y |
| Adjusted EBITDA · Q4-2025 | $1.18B | +13% y/y |
| Free cash flow · FY2025 | $2.53B | +127% y/y |
| Ambulatory segment net operating revenues · Ambulatory Care · Q4-2025 | $1.43B | +14% y/y |
| Same-facility system-wide net patient service revenues · Ambulatory Care · Q4-2025 | $2.39B | +7% y/y |
| Ambulatory Adjusted EBITDA · Ambulatory Care · Q4-2025 | $580M | +9% y/y |
| FY2026 Adjusted EBITDA outlook · FY2026 | $4.49B | |
| Net debt to Adjusted EBITDA ratio · 2025-12-31 | $2.25 | -11% y/y |
Guidance
FY2026 Adjusted EBITDA outlook $4.485B-$4.785B vs FY2025 $4.566B
Tenet provides FY2026 Adjusted EBITDA guidance above FY2025 actual, indicating continued growth and margin expansion.
Risks flagged
Transaction with CommonSpirit involves significant cash flows and tax payments, but is non-recurring.
“In 2026, Tenet will record approximately $1.65 billion of revenue from contract termination, approximately $500 million of tax expense, and make approximately $150 million of tax payments associated with the transaction.” · word for word
2 Feb 20268-K · 2.02, 7.01, 8.01Guidance: Adjusted EBITDA expected at upper end of $4.47B-$4.57B rangeearningsopen
Guidance
Adjusted EBITDA expected at upper end of $4.47B-$4.57B range
Adjusted EBITDA expected at upper end of guidance range, driven by strong same-store revenue growth and expense discipline.
24 Nov 20258-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Board composition change may signal governance shift, but no immediate operational risk.
“Resignation of a director, board size reduced from 13 to 12.”
18 Nov 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen
Risks flagged
Increased debt obligations may impact leverage, but terms not disclosed.
“Entry into supplemental indentures for existing debt facilities.”
5 Nov 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen
Risks flagged
Increased debt capacity may signal future capital needs, but terms not disclosed.
“Entry into new credit agreement and amendment to LC facility.”
3 Nov 20258-K · 7.01, 8.01Issued a Regulation FD disclosure (forward guidance or material update); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Debt refinancing risk is low as offering is upsized and priced; no operational risk signaled.
“Offering upsized from $2.0B to $2.25B, indicating strong demand; redemption of existing notes reduces near-term refinancing risk.”
28 Oct 202510-QQ3 2025 results: consolidated net operating revenues +3.2% YoY, same-hospital revenue +6.8%, Ambulatory Care revenue +11.9%, operating income margin 16.8%.earningsopen
Figures in the filing · each found in the filing text
| Same-hospital salaries, wages and benefits as % of net operating revenues · Hospital Operations · Q3-2025 | 47.1% | |
| Ambulatory Care same-facility net revenue growth · Ambulatory Care · Q3-2025 | 8.3% | |
| Ambulatory Care same-facility case growth · Ambulatory Care · Q3-2025 | 2.1% | |
| Ambulatory Care same-facility net revenue per case growth · Ambulatory Care · Q3-2025 | 6.1% | |
| Net cash provided by operating activities · 9M-2025 | $2.81B | +18% y/y |
| Share repurchases · 9M-2025 | $1.19B |
Risks flagged
Medicaid Policy Risk
“The OBBBA introduces new limitations and eligibility requirements that are expected to materially impact Medicaid funding and enrollment, as well as the health insurance marketplace.” · word for word
Tariff Input Cost Pressure
“The potential for new or increased tariffs on various goods including, but not limited to, medical supplies, pharmaceuticals and capital equipment and the potential impact to reimbursements and disruption in payments from the government shutdown have created further uncertainty within the healthcare sector.” · word for word
Litigation Liability Pressure
“Litigation and investigation costs (benefit) totaled $(11) million and $34 million during the three and nine months ended September 30, 2025, respectively.” · word for word
28 Oct 20258-K · 2.02Net operating revenues $5.29B (+3% y/y); Adjusted EBITDA $1.10B (+12% y/y); Adjusted diluted earnings per share $3.70 (+26% y/y); Guidance: FY 2025 Adjusted EBITDA guidance raised by $50M at the midpoint to $4.47B-$4.57Bearningsopen
Figures in the filing · each found in the filing text
| Net operating revenues · Q3-2025 | $5.29B | +3% y/y |
| Adjusted EBITDA · Q3-2025 | $1.10B | +12% y/y |
| Adjusted diluted earnings per share · Q3-2025 | $3.70 | +26% y/y |
| Free cash flow · 9M-2025 | $2.16B | +22% y/y |
| Ambulatory Care Adjusted EBITDA · Ambulatory Care · Q3-2025 | $492M | +12% y/y |
| Hospital Adjusted EBITDA · Hospital · Q3-2025 | $607M | +13% y/y |
| Same-facility system-wide net patient service revenues (Ambulatory) · Ambulatory Care · Q3-2025 | $2.11B | +8% y/y |
| Same-hospital net patient service revenues · Hospital · Q3-2025 | $3.42B | +8% y/y |
| Net debt to Adjusted EBITDA ratio · Q3-2025 | $2.30 |
Guidance
FY 2025 Adjusted EBITDA guidance raised by $50M at the midpoint to $4.47B-$4.57B
FY 2025 Adjusted EBITDA Outlook raised to $4.47B-$4.57B, a $50M increase at the midpoint.
Risks flagged
No significant risk signals; strong operational performance and balance sheet.
Tenet Healthcare Corporation — questions
- What did Tenet Healthcare Corporation file recently?
- 18 SEC filings in the last 12 months. Latest: 8-K on 2026-09-22 — Tenet Healthcare entered into a Forty-Third Supplemental Indenture for existing debt; no new issuance or material change disclosed.
Every figure on this page comes from Tenet Healthcare Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.